Market News
Global Cancer Supportive Care Product Market: Key Developments
- Major players in the market are focused on presenting new portfolios in order to enhance their market share. For instance, in September 2020, Merck a global pharmaceutical, chemical and life science company with a history that began in 1668 and a future shaped by approximately 50,000 employees in 66 countries . Merck announced that more than 30 abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21. The abstracts span the company's clinical program in oncology across several innovative modalities and mechanisms that have the potential to advance treatment across a range of tumor types including biliary tract, lung, and urothelial (bladder) cancers.
- In 28 December 2022, U.S. Food and Drug Administration (FDA) approved immunotherapy drug atezolizumab (Tecentriq) for the treatment of adults and children 2 years and older with Alveolar soft part sarcoma (ASPS) that has spread to other parts of the body or cannot be removed by surgery.
- In 21 March 2020, National Cancer Institute has launched the Molecular Characterization Initiative for pediatric tumors. This program offers tumor molecular characterization, also called biomarker testing, to children, adolescents, and young adults with newly diagnosed central nervous system tumors who are being treated at hospitals that are affiliated with the Children’s Oncology Group (COG)